These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 38287246

  • 1. Factors associated with immunological non-response after ART initiation: a retrospective observational cohort study.
    Zhao H, Feng A, Luo D, Yuan T, Lin YF, Ling X, Zhong H, Li J, Li L, Zou H.
    BMC Infect Dis; 2024 Jan 29; 24(1):138. PubMed ID: 38287246
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.
    Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM.
    PLoS One; 2016 Jan 29; 11(3):e0150512. PubMed ID: 26933963
    [Abstract] [Full Text] [Related]

  • 3. The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China.
    Li CX, Li YY, He LP, Kou J, Bai JS, Liu J, Tian B, Cao LJ, Wang KH, Kuang YQ.
    BMC Immunol; 2019 Aug 28; 20(1):31. PubMed ID: 31455209
    [Abstract] [Full Text] [Related]

  • 4. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S, Fairley CK, Sasadeusz J, He J, Wei X, Zeng H, Jing J, Mao L, Chen X, Zhang L.
    J Med Virol; 2018 Mar 28; 90(3):518-525. PubMed ID: 29091279
    [Abstract] [Full Text] [Related]

  • 5. CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment.
    Ryscavage P, Hussien S, Seung H, Hynicka L.
    HIV Med; 2024 May 28; 25(5):622-627. PubMed ID: 38273652
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
    van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L.
    PLoS One; 2014 May 28; 9(2):e88552. PubMed ID: 24533106
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients.
    Portocarrero Nuñez JA, Gonzalez-Garcia J, Berenguer J, Gallego MJV, Loyarte JAI, Metola L, Bernal E, Navarro G, Del Amo J, Jarrín I, and the Cohort of the Spanish HIV Research Network (CoRIS).
    Medicine (Baltimore); 2018 Sep 28; 97(38):e12238. PubMed ID: 30235668
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association between CD4+ T cell counts and gut microbiota and serum cytokines levels in HIV-infected immunological non-responders.
    Lu D, Zhang JB, Wang YX, Geng ST, Zhang Z, Xu Y, Li SY, Wang KH, Kuang YQ.
    BMC Infect Dis; 2021 Aug 03; 21(1):742. PubMed ID: 34344350
    [Abstract] [Full Text] [Related]

  • 14. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.
    Taye S, Lakew M.
    BMC Immunol; 2013 May 17; 14():23. PubMed ID: 23679118
    [Abstract] [Full Text] [Related]

  • 15. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.
    Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R, Vickerman P.
    AIDS; 2014 Jan 17; 28 Suppl 1():S35-46. PubMed ID: 24468945
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.
    Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E.
    BMC Res Notes; 2012 Jul 09; 5():180. PubMed ID: 22490728
    [Abstract] [Full Text] [Related]

  • 18. Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    da Silva CM, de Peder LD, Guelere AM, Horvath JD, Silva ES, Teixeira JJV, Bertolini DA.
    PLoS One; 2018 Jul 09; 13(9):e0203272. PubMed ID: 30192795
    [Abstract] [Full Text] [Related]

  • 19. Determinants of suboptimal immune recovery among a Chinese Yi ethnicity population with sustained HIV suppression.
    Chen L, Liu CH, Kang S, Du L, Ma F, Li C, Bai L, Li H, Tang H.
    BMC Infect Dis; 2022 Feb 08; 22(1):137. PubMed ID: 35135485
    [Abstract] [Full Text] [Related]

  • 20. Seroprevalence and effect of HBV and HCV co-infections on the immuno-virologic responses of adult HIV-infected persons on anti-retroviral therapy.
    Annison L, Hackman H, Eshun PF, Annison S, Forson P, Antwi-Baffour S.
    PLoS One; 2022 Feb 08; 17(11):e0278037. PubMed ID: 36417469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.